替罗非班对急性缺血性卒中患者神经功能恶化的影响:一项随机临床试验
这项由研究者发起的多中心、开放标签、终点盲法评估随机临床试验在中国10家综合卒中中心开展,纳入425例发病24小时内、NIHSS评分4至20分的急性非心源性栓塞性卒中患者,随机接受静脉替罗非班或口服阿司匹林治疗72小时。替罗非班组早期神经功能恶化发生9例(4.2%),阿司匹林组28例(13.2%)(校正相对风险0.32;95%CI 0.16-0.65;P=0.002);替罗非班组无患者发生脑出血。
要点
- 替罗非班较阿司匹林降低急性非心源性栓塞性卒中24小时内早期神经功能恶化风险。
- 替罗非班组早期神经功能恶化4.2%,阿司匹林组13.2%(校正RR 0.32;95%CI 0.16-0.65;P=0.002)。
- 替罗非班组无患者发生脑出血,90天死亡与改良Rankin量表评分两组无显著差异。
核心结论
- 在发病24小时内就诊的非心源性栓塞性卒中患者中,替罗非班降低了早期神经功能恶化风险,但未增加症状性脑出血或系统性出血风险。
研究设计与样本
- 由研究者发起、多中心、开放标签、终点盲法评估的随机临床试验,于2020年9月至2023年3月在中国10家综合卒中中心开展。
- 纳入年龄18至80岁、发病24小时内、NIHSS评分4至20分的急性非心源性栓塞性卒中患者,共425例。
- 患者按1:1随机分配接受静脉替罗非班(n=213)或口服阿司匹林(n=212)治疗72小时,之后所有患者均接受口服阿司匹林。
- 中位(IQR)年龄64.0岁(56.0-71.0);女性124例(29.2%),男性301例(70.8%)。
- 临床试验注册号:ClinicalTrials.gov NCT04491695。
主要发现
- 主要疗效结局早期神经功能恶化(随机化后72小时内NIHSS评分增加≥4分)在替罗非班组发生9例(4.2%),阿司匹林组发生28例(13.2%)(校正相对风险0.32;95%CI 0.16-0.65;P=0.002)。
- 替罗非班组无患者发生脑出血。
- 90天随访时,替罗非班组死亡3例(1.3%),阿司匹林组死亡3例(1.5%)(校正RR 1.15;95%CI 0.27-8.54;P=0.63)。
- 90天随访时,替罗非班组改良Rankin量表评分中位(IQR)1.0(0-1.25),阿司匹林组1.0(0-2)(校正比值比1.28;95%CI 0.90-1.83;P=0.17)。
关键数值与推荐
- 主要疗效结局为随机化后72小时内早期神经功能恶化,定义为NIHSS评分增加≥4分。
- 主要安全结局为随机化后72小时内症状性脑出血。
临床怎么用
- 对于发病24小时内就诊的非心源性栓塞性卒中患者,替罗非班降低了早期神经功能恶化风险,且未增加症状性脑出血或系统性出血风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Evidence supports using antiplatelet therapy in patients with acute ischemic stroke. However, neurological deterioration remains common under the currently recommended antiplatelet regimen, leading to poor clinical outcomes. OBJECTIVE: To determine whether intravenous tirofiban administered within 24 hours of stroke onset prevents early neurological deterioration in patients with acute noncardioembolic stroke compared with oral aspirin. DESIGN, SETTING, AND PARTICIPANTS: This investigator-initiated, multicenter, open-label, randomized clinical trial with blinded end-point assessment was conducted at 10 comprehensive stroke centers in China between September 2020 and March 2023. Eligible patients were aged 18 to 80 years with acute noncardioembolic stroke within 24 hours of onset and had a National Institutes of Health Stroke Scale (NIHSS) score of 4 to 20. INTERVENTION: Patients were assigned randomly (1:1) to receive intravenous tirofiban or oral aspirin for 72 hours using a central, web-based, computer-generated randomization schedule; all patients then received oral aspirin. MAIN OUTCOME: The primary efficacy outcome was early neurological deterioration (increase in NIHSS score ≥4 points) within 72 hours after randomization. The primary safety outcome was symptomatic intracerebral hemorrhage within 72 hours after randomization. RESULTS: A total of 425 patients were included in the intravenous tirofiban (n = 213) or oral aspirin (n = 212) groups. Median (IQR) age was 64.0 years (56.0-71.0); 124 patients (29.2%) were female, and 301 (70.8%) were male. Early neurological deterioration occurred in 9 patients (4.2%) in the tirofiban group and 28 patients (13.2%) in the aspirin group (adjusted relative risk, 0.32; 95% CI, 0.16-0.65; P = .002). No patients in the tirofiban group experienced intracerebral hemorrhage. At 90-day follow-up, 3 patients (1.3%) in the tirofiban group and 3 (1.5%) in the aspirin group died (adjusted RR, 1.15; 95% CI, 0.27-8.54; P = .63), and the median (IQR) modified Rankin scale scores were 1.0 (0-1.25) and 1.0 (0-2), respectively (adjusted odds ratio, 1.28; 95% CI, 0.90-1.83; P = .17). CONCLUSIONS AND RELEVANCE: In patients with noncardioembolic stroke who were seen within 24 hours of symptom onset, tirofiban decreased the risk of early neurological deterioration but did not increase the risk of symptomatic intracerebral hemorrhage or systematic bleeding. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04491695.
引用
- Zhao W, Li S, Li C, et al. Effects of Tirofiban on Neurological Deterioration in Patients With Acute Ischemic Stroke: A Randomized Clinical Trial. JAMA Neurol. 2024. PMID: 38648030. doi:10.1001/jamaneurol.2024.0868
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。